
Just about every company these days is grappling with the arrival of Artificial Intelligence (AI). But what should companies be telling their investors about the impact of AI deployment on their operations and financial results? At a recent meeting, the SEC’s Investment Advisory Committee recommended that the agency issue guidance requiring issuers to provide disclosures about the impact on the company from AI. As discussed below, while the committee’s recommendations may be unlikely to cause the agency to issue AI disclosure rules or guidance, the committee’s recommendations do provide a useful framwork to consider corporate AI-related disclosure best practices.Continue Reading SEC Investor Advisory Committee Recommends AI-Related Disclosure Guidelines




As I discussed at the time (
On March 9, 2022, the SEC finally released its long-anticipated updated cybersecurity disclosure requirements. The proposed rules, inclusive of specifications both for incident reporting and for risk management and governance disclosure, were adopted by a 3-1 vote and are now subject to a public reporting period. The new rules, which the Commission’s press release says are “designed to better inform investors about a registrant’s risk management, strategy, and governance and to provide timely notification of material cybersecurity incidents,” underscore the Commission’s emphasis on cybersecurity reporting and disclosure issues.

In the latest sign that COVID-19 related securities litigation is on track to continue into 2021, a plaintiff shareholder has filed a securities class action lawsuit against Tyson Foods, Inc. relating to the company’s disclosures and actions in its facilities pertaining to the coronavirus outbreak. The plaintiff’s February 2, 2021 complaint can be found
If you have not yet seen SEC Commissioner Allison Herren Lee’s speech delivered last week to the PLI’s annual Institute on Securities Litigation, you should take a few minutes and read what she had to say. In her November 5, 2020 speech, which can be found
As the coronavirus outbreak has spread, the COVID-19 disease has struck millions across the globe. The demographics and geographic distribution of the disease will make for interesting study when the current outbreak has ended, but clearly the disease has struck both the mighty and modest. The high-profile victims include the Prince of Wales and the U.K. Prime Minister. Other victims have included (and likely will continue to include) senior corporate executives. When key execs contract the disease, their companies face the question whether the executives’ illness must be disclosed. As discussed in Judy Greenwald’s April 21, 2020 Business Insurance article (